MVA Brachyury TRICOM vaccine - Bavarian Nordic
Alternative Names: BN-Brachyury; Brachyury/TRICOM; MVA-BN-Brachyury vaccine; MVA-BN-Brachyury/ FPV-Brachyury; MVA-brachyury-TRICOMLatest Information Update: 26 Nov 2024
Price :
$50 *
At a glance
- Originator Bavarian Nordic
- Developer Bavarian Nordic; National Cancer Institute (USA); University of Utah
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Chordoma
- Phase I/II Prostate cancer; Solid tumours
Most Recent Events
- 08 Oct 2024 National Cancer Institute completes a QuEST1 phase-I/II clinical trial in Prostate cancer (Combination therapy, Hormone-refractory, Late-stage disease) in the USA (SC) (NCT03493945)
- 08 Oct 2024 National Cancer Institute completes the QuEST1 phase I/II trial for Solid tumours (Combination therapy, Metastatic disease, Second line therapy or greater) in USA (SC)(NCT03493945)
- 13 Sep 2024 Efficacy and adverse event data from the phase I/II QuEST1 trial in Prostate cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)